The recombinant EGF-CRM197 tumor therapeutic vaccine is a novel vaccine developed by Shanghai Humantech Biotechnology Co., Ltd. The preclinical data including safety and efficacy of EGF-CRM197 vaccine have been submitted to the Center for Drug Evaluation (CDE) of China and approved for clinical trial by the CDE (Approval No.:2017L04930). This evidence concerns the gene EGF and neoplasm.